<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We evaluated the effect of <z:hpo ids='HP_0011010'>chronic</z:hpo> administration of <z:chebi fb="0" ids="16436,49086">CDP-choline</z:chebi>, an intermediate of <z:chebi fb="0" ids="16247">phospholipid</z:chebi> synthesis, on outcome from middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, ranging from 30 to 120 min in duration in spontaneously hypertensive rats </plain></SENT>
<SENT sid="1" pm="."><plain>Rats were randomly assigned to either <z:chebi fb="0" ids="16436,49086">CDP-choline</z:chebi> 500 mg kg-1 or saline </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="16436,49086">CDP-choline</z:chebi> treatment was initiated by intraperitoneal injection 15 min after the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and continued once a day for 14 days </plain></SENT>
<SENT sid="3" pm="."><plain>Morphologic damage and behavioral dysfunction (motor and sensorimotor performance) were evaluated, and the maximal morphologic damage (Volmax), maximal behavioral dysfunction (BDmax) as well as the duration of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> producing half-maximal morphologic damage (T50) or behavioral dysfunction (BD50) were calculated using a curve-fitting program (ALLFIT) </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e> in control animals produced a Volmax of 103.3 +/- 13.6 mm3 </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="16436,49086">CDP-choline</z:chebi> did not affect this value (Volmax of 101.6 +/- 11.4 mm3) </plain></SENT>
<SENT sid="6" pm="."><plain>However, <z:chebi fb="0" ids="16436,49086">CDP-choline</z:chebi> significantly extended the T50 from 38.3 +/- 5.9 to 60.5 +/- 4.3 min (p &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>Similar to the morphologic outcome, <z:chebi fb="0" ids="16436,49086">CDP-choline</z:chebi> had no effect on BDmax but significantly extended BD50 from 41.9 +/- 4.6 to 72.9 +/- 24.5 min (p &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>Our results suggest that the effectiveness of <z:chebi fb="0" ids="16436,49086">CDP-choline</z:chebi> is greater in animals demonstrating submaximal ischemic injury which in this model is produced by 30-75 min of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> (effect on T50 and BD50), than in animals suffering maximal ischemic injury produced by <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> longer than 75 min (no effect on Volmax and BDmax) </plain></SENT>
<SENT sid="9" pm="."><plain>These results may reflect a threshold of biological membrane damage within which <z:chebi fb="0" ids="16436,49086">CDP-choline</z:chebi> is able to restore <z:chebi fb="0" ids="16247">phospholipid</z:chebi> content/arrangement and retain membrane integrity </plain></SENT>
</text></document>